Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2020 4
2021 8
2022 14
2023 10
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Linzagolix: First Approval.
Keam SJ. Keam SJ. Drugs. 2022 Aug;82(12):1317-1325. doi: 10.1007/s40265-022-01753-9. Drugs. 2022. PMID: 35997940 Free PMC article. Review.
In June 2022, linzagolix was approved for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age in the EU. Linzagolix is under regulatory review the USA for this indication and is in phase 3 clinical development in the t …
In June 2022, linzagolix was approved for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproduc …
Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.
Donnez J, Taylor HS, Stewart EA, Bradley L, Marsh E, Archer D, Al-Hendy A, Petraglia F, Watts N, Gotteland JP, Bestel E, Terrill P, Loumaye E, Humberstone A, Garner E. Donnez J, et al. Lancet. 2022 Sep 17;400(10356):896-907. doi: 10.1016/S0140-6736(22)01475-1. Lancet. 2022. PMID: 36116480 Clinical Trial.
Eligible women with uterine fibroid-associated heavy menstrual bleeding (menstrual blood loss >80 mL per cycle) were randomly assigned in a 1:1:1:1:1 ratio to one of five masked treatments: (1) placebo, (2) 100 mg linzagolix per day alone, (3) 100 mg linzagolix p …
Eligible women with uterine fibroid-associated heavy menstrual bleeding (menstrual blood loss >80 mL per cycle) were randomly assigned in …
Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas.
Dababou S, Garzon S, Laganà AS, Ferrero S, Evangelisti G, Noventa M, D'Alterio MN, Palomba S, Uccella S, Franchi M, Barra F. Dababou S, et al. Expert Opin Investig Drugs. 2021 Sep;30(9):903-911. doi: 10.1080/13543784.2021.1957830. Epub 2021 Aug 4. Expert Opin Investig Drugs. 2021. PMID: 34278887 Review.
AREA COVERED: This drug evaluation highlights definitive and preliminary results from previous and ongoing studies of linzagolix for the treatment of endometriosis and myomas. EXPERT OPINION: Linzagolix showed a dose-dependent and rapidly reversible action on the pi …
AREA COVERED: This drug evaluation highlights definitive and preliminary results from previous and ongoing studies of linzagolix for …
Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial.
Donnez J, Taylor HS, Taylor RN, Akin MD, Tatarchuk TF, Wilk K, Gotteland JP, Lecomte V, Bestel E. Donnez J, et al. Fertil Steril. 2020 Jul;114(1):44-55. doi: 10.1016/j.fertnstert.2020.02.114. Epub 2020 Jun 4. Fertil Steril. 2020. PMID: 32505383 Free article. Clinical Trial.
INTERVENTION(S): The interventions were 50, 75, 100, or 200 mg linzagolix (or matching placebo) administered once daily for 24 weeks. ...BMD of femoral neck and total hip showed a similar pattern. CONCLUSION(S): Linzagolix significantly reduced EAP and improved QoL …
INTERVENTION(S): The interventions were 50, 75, 100, or 200 mg linzagolix (or matching placebo) administered once daily for 24 weeks. …
Profile of Linzagolix in the Management of Endometriosis, Including Design, Development and Potential Place in Therapy: A Narrative Review.
Donnez J, Cacciottola L, Squifflet JL, Dolmans MM. Donnez J, et al. Drug Des Devel Ther. 2023 Feb 8;17:369-380. doi: 10.2147/DDDT.S269976. eCollection 2023. Drug Des Devel Ther. 2023. PMID: 36789095 Free PMC article. Review.
The first publication on these drugs reported the efficacy of elagolix. The present paper is a narrative review of linzagolix, which is an orally administered GnRH receptor antagonist with low pharmacokinetic/pharmacodynamic variability. ...There is a place for GnRH antago …
The first publication on these drugs reported the efficacy of elagolix. The present paper is a narrative review of linzagolix, which …
Novel pharmacological therapies for the treatment of endometriosis.
Buggio L, Dridi D, Barbara G, Merli CEM, Cetera GE, Vercellini P. Buggio L, et al. Expert Rev Clin Pharmacol. 2022 Sep;15(9):1039-1052. doi: 10.1080/17512433.2022.2117155. Epub 2022 Aug 30. Expert Rev Clin Pharmacol. 2022. PMID: 36000243 Free article. Review.
Pharmacological characterization of linzagolix, a novel, orally active, non-peptide antagonist of gonadotropin-releasing hormone receptors.
Tezuka M, Tamai Y, Kuramochi Y, Kobayashi K, Fushimi N, Kiguchi S. Tezuka M, et al. Clin Exp Pharmacol Physiol. 2022 Oct;49(10):1082-1093. doi: 10.1111/1440-1681.13688. Epub 2022 Jul 12. Clin Exp Pharmacol Physiol. 2022. PMID: 35690889
Here, we reported the pharmacological characterization of linzagolix in vitro and in vivo. Linzagolix selectively binds to the GnRH receptor and inhibits GnRH-stimulated signalling, in a manner comparable to cetrorelix, a peptide GnRH antagonist. ...In ovariectomize …
Here, we reported the pharmacological characterization of linzagolix in vitro and in vivo. Linzagolix selectively binds to the …
Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis.
Donnez O, Donnez J. Donnez O, et al. Fertil Steril. 2020 Sep;114(3):640-645. doi: 10.1016/j.fertnstert.2020.04.017. Epub 2020 Jun 2. Fertil Steril. 2020. PMID: 32507315 Free article.
OBJECTIVE: To compare the efficacy of a selective progesterone receptor modulator, ulipristal acetate, and a gonadotropin-releasing hormone antagonist, linzagolix, in a case of severe uterine adenomyosis. DESIGN: Case report. ...This therapy was discontinued because MRI re …
OBJECTIVE: To compare the efficacy of a selective progesterone receptor modulator, ulipristal acetate, and a gonadotropin-releasing hormone …
39 results